Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 3, 2009, Pages 718-726

  Sun, Cheuk Kwan ^a   Lee, Fan Yen ^a   Sheu, Jiunn Jye ^a   Yuen, Chun Man ^a   Chua, Sarah ^a   Chung, Sheng Ying ^a   Chai, Han Tan ^a   Chen, Yen Ta ^a   Kao, Ying Hsien ^a   Chang, Li Teh ^b   Yip, Hon Kan ^a,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CILOSTAZOL; CONNEXIN 43; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; MESSENGER RNA; MONOCROTALINE; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HEART RIGHT VENTRICLE; HEART VENTRICLE SEPTUM; HEMODYNAMICS; LUNG ALVEOLUS; LUNG PARENCHYMA; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RAT; STEM CELL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; ENDOTHELIAL CELLS; FLUORESCENT DYES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODYNAMICS; HYPERTENSION, PULMONARY; LUNG; MALE; MEMBRANE PROTEINS; MONOCROTALINE; MYOCARDIUM; PHENOTYPE; POISONS; PULMONARY ALVEOLI; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLES; VASODILATOR AGENTS;

EID: 70349092330     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.154328     Document Type: Article

References (39)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609-616. (Pubitemid 26277950)
2. Anand IS, Prasad BA, Chugh SS, Rao KR, Cornfield DN, Milla CE, Singh N, Singh S, and Selvamurthy W (1998) Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema. Circulation 98:2441-2445. (Pubitemid 28549789)
3. Archer S and Rich S (2000) Primary pulmonary hypertension: a vascular biology and translational research "work in progress". Circulation 102:2781-2791.
4. Asahara T and Kawamoto A (2004) Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 287:C572-C579. (Pubitemid 39095841)
5. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, et al. (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425-434. (Pubitemid 30149039)
6. Barst RJ, Maislin G, and Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197-1208. (Pubitemid 29120092)
7. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, and Brundage BH (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296-302.
8. Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, Wu CJ, and Yip HK (2008) Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. Circ J 72:825-831.
9. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, et al. (2001) Effects of dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. Lancet 358:1119-1123. (Pubitemid 32971843)
10. Chen YM, Chiang WC, Lin SL, Wu KD, Tsai TJ, and Hsieh BS (2004) Dual regulation of tumor necrosis factor-α-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-κB and activator protein-1: modulation by type III phosphodiesterase inhibition. J Pharmacol Exp Ther 309:978-986.
11. Chen YM, Tu CJ, Hung KY, Wu KD, Tsai TJ, and Hsieh BS (2003) Inhibition by pentoxifylline of TNF-α-stimulated fractalkine production in vascular smooth cells: evidence for mediation by NF-B down-regulation. Br J Pharmacol 138:950-958.
12. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, and Kernis JT (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Int Med 115:343-349.
13. Davani S, Marandin A, Mersin N, Royer B, Kantelip B, Hervé P, Etievent JP, and Kantelip JP (2003) Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 108 (Suppl 1):II253-II258. (Pubitemid 37099964)
14. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, et al. (2005) Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826-2832.
15. Dutly AE, Kugathasan L, Trogadis JE, Keshavjee SH, Stewart DJ, and Courtman DW (2006) Fluorescent microangiography (FMA): an improved tool to visualize the pulmonary microvasculature. Lab Invest 86:409-416.
16. Gaine SP and Rubin LJ (1998) Primary pulmonary hypertension. Lancet 352:719-725.
17. Galiè N, Manes A, and Branzi A (2002) Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 45:213-224. (Pubitemid 36139817)
18. Kalra L and Bone MF (1993) Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. Am J Med 94:419-423. (Pubitemid 23106630)
19. Kirchhoff S, Nelles E, Hagendorff A, Krüger O, Traub O, and Willecke K (1998) Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice. Curr Biol 8:299-302. (Pubitemid 28111463)
20. Koh ET, Lee P, Gladman DD, and Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989-993. (Pubitemid 126719617)
21. Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishimine K, Makutani S, Sakaguchi S, Yoshioka T, Ohishi H, and Kimura Y (1995) Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: an experimental study. Invest Radiol 30:532-537.
22. Lerner DL, Yamada KA, Schuessler RB, and Saffitz JE (2000) Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 101:547-552.
23. Luttun A, Carmeliet G, and Carmeliet P (2002) Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 12:88-96.
24. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, and Polson JB (1994) Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isoenzyme families PDE III and PDE IV to attenuate proliferation rate of vascular smooth muscle cells. Biochem Pharmacol 48:827-835. (Pubitemid 24283854)
25. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, and Detre KM (1989) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80:1198-1206. (Pubitemid 19282508)
26. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, and Komajda M (1997) Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18:254-258. (Pubitemid 27107587)
27. Reffelmann T and Kloner RA (2003) Cellular cardiomyoplasty: cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure. Cardiovasc Res 58:358-368. (Pubitemid 36570394)
28. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. New Engl J Med 346:896-903. (Pubitemid 34984638)
29. Runo JR and Loyd JE (2003) Primary pulmonary hypertension. Lancet 361:1533-1544.
30. Sanchez O, Humbert M, Sitbon O, and Simonneau G (1999) Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 54:273-277. (Pubitemid 29110511)
31. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, et al. (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355:1210-1221. (Pubitemid 44427445)
32. Sun CK, Chang LT, Sheu JJ, Chiang CH, Lee FY, Wu CJ, Chua S, Fu M, and Yip HK (2009) Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat dilated cardiomyopathy. Crit Care Med 37:1197-1205.
33. Thompson PD, Zimet R, Forbes WP, and Zhang P (2002) Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90:1314-1319. (Pubitemid 35449476)
34. Thum T, Bauersachs J, Poole-Wilson PA, Volk HD, and Anker SD (2005) The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 46:1799-1802. (Pubitemid 41579799)
35. Uzzaman M, Honjo H, Takagishi Y, Emdad L, Magee AI, Severs NJ, and Kodama I (2000) Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension. Circ Res 86:871-878. (Pubitemid 30246984)
36. Yeh HI, Lai YJ, Lee SH, Lee YN, Ko YS, Chen SA, Severs NJ, and Tsai CH (2001) Heterogeneity of myocardial sleeve morphology and gap junctions in canine superior vena cava. Circulation 104:3152-3157.
37. Yip HK, Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, Wu CJ, and Fu M (2008) Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Crit Care Med 36:873-880.
38. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, et al. (2005) Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 112:1618-1627. (Pubitemid 41324524)
39. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, and Stewart DJ (2005) Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96:442-450. (Pubitemid 40354538)